You are here

ubrogepant

AbbVie’s Migraine Drug Ubrelvy Scores Victory in Phase III Study

AbbVie’s Migraine Drug Ubrelvy Scores Victory in Phase III Study

BioSpace

clinical trials

Flag link:

In final report, ICER appears to have a change of heart on new acute migraine therapies

In final report, ICER appears to have a change of heart on new acute migraine therapies

Endpoints

Flag link:

Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch

Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch

Fierce Pharma

Flag link:

3 Biotechs Facing FDA Approvals by Year's End

3 Biotechs Facing FDA Approvals by Year's End

Motley Fool

Intra-Cellular Therapies

Flag link:

Go or no go? Vascepa’s finale and Allergan's pain relief

Go or no go? Vascepa’s finale and Allergan's pain relief

EP Vantage

Flag link:

Before 2019 closes, the FDA has 3 key approval decisions to make

Before 2019 closes, the FDA has 3 key approval decisions to make

Biopharma Dive

Intra-Cellular Therapeutics

bipolar disorder

Flag link:

Allergan builds case for migraine drug ubrogepant as FDA verdict nears

Allergan builds case for migraine drug ubrogepant as FDA verdict nears

Pharmaforum

Flag link:

Allergan's NDA for Migraine Med With Novel Mechanism of Action Accepted by FDA

Allergan's NDA for Migraine Med With Novel Mechanism of Action Accepted by FDA

BioSpace

Flag link:

Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant

Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant

Endpoints

clinical trials

Flag link:

Will Allergan cannibalize Botox with ubrogepant?

Will Allergan cannibalize Botox with ubrogepant?

Biopharma Dive

Flag link:

As Migraine Races Heat Up, Allergan Touts New Data for Headache Pill

As Migraine Races Heat Up, Allergan Touts New Data for Headache Pill

Xconomy

Flag link: